Trusted News Discovery Since 2008
{{/content}}
United States: Biocon Settles With Janssen, Securing U.S. Market Entry Date For Ustekinumab Biosimilar - Goodwin Procter LLP
Credit: Mondaq- Published on March 15, 2024
On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson ("J&J") regarding Bmab 1200, Biocon's proposed biosimilar to STELARA.
You are here
Related news from verified sources
On March 4, Biocon Biologics Ltd. announced it has signed a settlement agreement with Bayer Inc. and Regeneron Pharmaceuticals, Inc. regarding YESAFILI, Biocon's...
on March 15, 2024 • Mondaq